Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Apolipoprotein A-I (ApoA-I) is the major structural and functional protein component of high-density lipoprotein (HDL), playing a central role in reverse cholesterol transport, cardiovascular protection, and immune modulation. It facilitates cholesterol efflux from peripheral tissues and acts as a cofactor for LCAT. Defects in APOA1 are linked to Tangier disease and amyloidosis, while low levels are associated with increased cardiovascular risk. It can also bind endotoxins and influence inflammation.
N/A
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Apolipoprotein A-I (ApoA-I).